ProPhase Labs, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 711 STEWART AVE, SUITE 200, NEW YORK, NY, 11530
Mailing Address 711 STEWART AVE, SUITE 200, NEW YORK, NY, 11530
Phone (215) 345-0919
Fiscal Year End 1231
EIN 232577138
Financial Overview
FY2024
-$16.78M
Net Income
$63.20M
Total Assets
$55.85M
Total Liabilities
$63.63M
Stockholders' Equity
$1.61M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| 8-K Current report of material events | January 27, 2026 | View on SEC |
| 8-K Current report of material events | January 23, 2026 | View on SEC |
| 8-K Current report of material events | January 23, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 8-K Current report of material events | January 2, 2026 | View on SEC |
| 424B5 Prospectus supplement | December 29, 2025 | View on SEC |
| 8-K Current report of material events | December 19, 2025 | View on SEC |
Material Events
8-K Strategy Change January 27, 2026
High Impact
- Proactive initiative ('Crown Medical Collections') launched to recover unpaid bills from past diagnostic operations.
- Aims to generate much-needed cash flow for bankrupt subsidiaries (ProPhase Diagnostics, Inc. and Pharmatech, Inc.) to satisfy creditor claims.
8-K Strategy Change January 9, 2026
High Impact
- ProPhase Labs clarified that recent stock volatility is due to technical financial adjustments, including a major debt conversion, reverse stock split, and delisting from Nasdaq to the OTC market.
- Over $3.3 million of convertible debt (out of $3.8 million outstanding) has been converted into shares, significantly reducing the company's debt burden to less than $500,000.
8-K Financial Distress January 2, 2026
High Impact
- ProPhase Labs, Inc. is being delisted from the Nasdaq stock exchange due to failure to maintain the minimum $1.00 bid price requirement.
- The company received the official delisting letter on December 29, 2025, with trading suspension on Nasdaq scheduled for January 5, 2026.
8-K Strategy Change December 12, 2025
High Impact
- ProPhase Labs, Inc. completed a 1-for-10 reverse stock split of its common stock.
- The primary purpose of the reverse stock split was to increase the per-share trading price to meet NASDAQ's continued listing requirements.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.